Sam Ho

Dr. Sam Ho

1. Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
LGLynnette C. Goatley
Lynnette C. Goatley
ARAna Reis
Ana Reis
RPRaquel Portugal
Raquel Portugal
HGHannah Goldswain
Hannah Goldswain
GSGareth L. Shimmon
Gareth L. Shimmon
CNChristopher Netherton
Christopher Netherton
Classical approaches to African swine fever virus (ASFV) vaccine development have not been successful; inactivated virus does not provide protection and use of live attenuated viruses generated by passage in tissue culture had a poor safety profile. Current African swine fever (ASF) vaccine research focuses on the development of modified live viruses by targeted gene deletion or subunit vaccines. The latter approach would be differentiation of vaccinated from infected animals (DIVA)-compliant, but information on which viral proteins to include in a subunit vaccine is lacking. Our previous work used DNA-prime/vaccinia-virus boost to screen 40 ASFV genes for immunogenicity, however this immunization regime did not protect animals after challenge. Here we describe the induction of both antigen and ASFV-specific antibody and cellular immune responses by different viral-vectored pools of antigens selected based on their immunogenicity in pigs. Immunization with one of these pools, comprising eight viral-vectored ASFV genes, protected 100% of pigs from fatal disease after challenge with a normally lethal dose of virulent ASFV. This data provide the basis for the further development of a subunit vaccine against this devastating disease.

9 May 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JSJan Strnadel
Jan Strnadel
CCCassiano Carromeu
Cassiano Carromeu
CBCedric Bardy
Cedric Bardy
MNMichael Navarro
Michael Navarro
OPOleksandr Platoshyn
Oleksandr Platoshyn
MMMartin Marsala
Martin Marsala
Syngeneic iPSC–derived neurons survive and mature without immunosuppression after grafting into the spinal cord of adult pigs.

6 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCChung J. Chungwon
Chung J. Chungwon
SCSang-ho Cha
Sang-ho Cha
AGAmanda L Grimm
Amanda L Grimm
DADharani Ajithdoss
Dharani Ajithdoss
JRJoanna Rzepka
Joanna Rzepka
Sam HoSam Ho
Sam Ho
Porcine reproductive and respiratory syndrome virus (PRRSV) infection is difficult to control because the virus undergoes antigenic variation during infection and also modulates the protective host immune response. Although current vaccines do not provide full protection, they have provided insight into the mechanisms of protection. Live PRRSV vaccines induce partial protection before the appearance of neutralizing antibody, suggesting cell-mediated immunity or other mechanisms may be involved. Herein, we demonstrate recovery from infection is associated with development of cytotoxic T-lymphocytes (CTL) that can kill PRRSV-infected target cells. Initial experiments showed survival of PRRSV-infected monocyte derived macrophage (MDM) targets is reduced when overlaid with peripheral blood mononuclear cells (PBMC) from gilts that had recovered from PRRSV infection. Further studies with PBMC depleted of either CD4+ or CD8+ T-cells and positively selected subpopulations of CD4+ and CD8+ T-cells showed that both CD4+ and CD8+ T-cells were involved in killing. Examination of killing at different time points revealed killing was biphasic and mediated by CTL of different phenotypes. CD4+CD8+high were associated with killing target cells infected for 3–6 hours. CD4+CD8- CTL were associated with killing at 16–24 hours. Thus, all the anti-PRRSV CTL activity in pigs was attributed to two phenotypes of CD4+ cells which is different from the anti-viral CD4-CD8+ CTL phenotype found in most other animals. These findings will be useful for evaluating CTL responses induced by current and future vaccines, guiding to a novel direction for future vaccine development.


14 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sam HoSam Ho
Sam Ho
KPKyle R. Putnam
Kyle R. Putnam
CPChristine R. Peiter
Christine R. Peiter
WHWalter F. Herczyk
Walter F. Herczyk
JGJohn A. Gerlach
John A. Gerlach
MCMatthew F. Cusick
Matthew F. Cusick
We report the first case of Daratumumab interference of allogeneic crossmatch tests repeatedly causing aberrant false-positive results, which inadvertently delayed transplant for a waitlisted renal patient with multiple myeloma. Daratumumab is an IgG1κ human monoclonal antibody commonly used to treat multiple myeloma, characterized by cancerous plasma cells and often leads to renal failure requiring kidney transplant, by depleting CD38-expressing plasma cells. In this case study, the patient had end-stage renal disease secondary to multiple myeloma and was continuously receiving Daratumumab infusions. The patient did not have any detectable antibodies to human leukocyte antigens but repeatedly had unexpected positive crossmatch by the flow cytometry-based method with 26 of the 27 potential deceased organ donors, implying donor-recipient immunological incompatibility. However, further review and analysis suggested that the positive crossmatches were likely false-positive as a result of interference from Daratumumab binding to donor cell surface CD38 as opposed to the presence of donor-specific antibodies. The observed intensity of the false-positive crossmatches was also highly variable, potentially due to donor- and/or cell-dependent expression of CD38. The variability of CD38 expression was, therefore, for the first time, characterized on the T and B cells isolated from various tissues and peripheral blood of 78 individuals. Overall, T cells were found to have a lower CD38 expression profile than the B cells, and no significant difference was observed between deceased and living individuals. Finally, we show that a simple cell treatment by dithiothreitol can effectively mitigate Daratumumab interference thus preserving the utility of pre-transplant crossmatch in multiple myeloma patients awaiting kidney transplant.

15 December 2021 in Animal Genetics
Verified
Journal Article
Closed access
PDF file
SYS. Youk
S. Youk
MLM.T. Le
M.T. Le
MKM. Kang
M. Kang
BAByeongyong Ahn
Byeongyong Ahn
MCM. Choi
M. Choi
CPchankyu Park
chankyu Park